| NDC Code | 50242-260-86 |
|---|
| Package Description | 1 VIAL, SINGLE-DOSE in 1 CARTON (50242-260-86) > 10 mL in 1 VIAL, SINGLE-DOSE |
|---|
| Product NDC | 50242-260 |
|---|
| Product Type Name | HUMAN PRESCRIPTION DRUG |
|---|
| Proprietary Name | Phesgo |
|---|
| Non-Proprietary Name | Pertuzumab, Trastuzumab, And Hyaluronidase-zzxf |
|---|
| Dosage Form | INJECTION, SOLUTION |
|---|
| Usage | SUBCUTANEOUS |
|---|
| Start Marketing Date | 20200629 |
|---|
| Marketing Category Name | BLA |
|---|
| Application Number | BLA761170 |
|---|
| Manufacturer | Genentech, Inc. |
|---|
| Substance Name | HYALURONIDASE (HUMAN RECOMBINANT); PERTUZUMAB; TRASTUZUMAB |
|---|
| Strength | 20000; 600; 600 |
|---|
| Strength Unit | U/10mL; mg/10mL; mg/10mL |
|---|
| Pharmacy Classes | Endoglycosidase [EPC], Glycoside Hydrolases [CS], HER2/Neu/cerbB2 Antagonists [MoA], HER2/Neu/cerbB2 Antagonists [MoA], HER2/neu Receptor Antagonist [EPC], HER2/neu Receptor Antagonist [EPC] |
|---|